Evidence map›Paper›PMID 37199870›Full record

ReviewBiologia futura2023

The importance of equally accessible genomic surveillance in the age of pandemics.

Safia Zeghbib, Gábor Kemenesi, Ferenc Jakab

Abstract readReview
In one paragraph

Review in Biologia futura, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Safia ZeghbibNational Laboratory of Virology, Szentágothai Research Centre, University of Pécs, Pecs, Hungary. zeghbib.safia@gmail.com.
Gábor KemenesiNational Laboratory of Virology, Szentágothai Research Centre, University of Pécs, Pecs, Hungary.
Ferenc JakabNational Laboratory of Virology, Szentágothai Research Centre, University of Pécs, Pecs, Hungary.

Funding

Nemzeti Kutatási, Fejlesztési és Innovaciós Alap TKP2021- EGA-13Nemzeti Kutatási, Fejlesztési és Innovaciós Alap TKP2021-NVA-07
6 · The paper itself

Abstract

Genomic epidemiology is now a core component in investigating the spread of a disease during an outbreak and for future preparedness to tackle emerging zoonoses. During the last decades, several viral diseases arose and emphasized the importance of molecular epidemiology in tracking the dispersal route, supporting proper mitigation measures, and appropriate vaccine development. In this perspective article, we summarized what has been done so far in the genomic epidemiology field and what should be considered in the future. We traced back the methods and protocols employed over time for zoonotic disease response. Either to small outbreaks such as the severe acute respiratory syndrome (SARS) outbreak identified first in 2002 in Guangdong, China, or to a global pandemic like the one that we are experiencing now since 2019 when the severe acute respiratory syndrome 2 (SARS-CoV-2) virus emerged in Wuhan, China, following several pneumonia cases, and subsequently spread worldwide. We explored both the benefits and shortages encountered when relying on genomic epidemiology, and we clearly present the disadvantages of inequity in accessing these tools around the world, especially in countries with less developed economies. For effectively addressing future pandemics, it is crucial to work for better sequencing equity around the globe.

Indexed as

COVID-19SARS-CoV-2AnimalsGenomicsPandemicsZoonosesDisease containmentGenomic epidemiologyPandemicSequencingSequencing equity

Identifiers

PMID37199870
PMCPMC10193332

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.